Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
- Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
- Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
Zoetis Price Performance
ZTS stock opened at $74.32 on Wednesday. The stock has a 50-day moving average price of $73.85 and a two-hundred day moving average price of $84.06. Zoetis Inc. has a 12-month low of $68.77 and a 12-month high of $148.30. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.71 billion, a PE ratio of 12.24, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74.
Zoetis Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. J. Stern & Co. LLP boosted its stake in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. Flossbach Von Storch SE acquired a new position in Zoetis during the 2nd quarter worth $302,601,000. BlackRock Inc. increased its position in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new stake in shares of Zoetis in the 1st quarter worth about $286,660,000. Finally, Southpoint Capital Advisors LP increased its position in shares of Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock worth $260,062,000 after purchasing an additional 1,700,000 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ZTS has been the subject of a number of research reports. Cantor Fitzgerald set a $94.00 target price on Zoetis in a report on Tuesday, August 25th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Zoetis in a research note on Wednesday, September 9th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. Finally, Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $101.08.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Zoetis
Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.
The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.
Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.
Featured Articles
- Five stocks we like better than Zoetis
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
